Inventor · disambiguated record
David Malcolm Crowe
Also filed as: CROWE DAVID · CROWE DAVID M · CROWE DAVID MALCOLM
12 granted patents·9 pending applications·74 citations·filing 2002–2023
90Inventor score
Files withKALVISTA PHARMACEUTICALS LTD7ASCENEURON SA4SMITHKLINE BEECHAM CORP2STERIMBAUM GRETA2CRAIG ANDREW S1
Top patents by PatentIndex Score
21 records- 0196US11591327B2Acid addition salts of piperazine derivativesASCENEURON SA·Filed 2020·Granted Feb 28, 2023·6 cites·4 claims
- 0294US10696668B2Acid addition salts of piperazine derivativesASCENEURON SA·Filed 2017·Granted Jun 30, 2020·12 cites·2 claims
- 0385US8227477B2Nilotinib HCl crystalline formsSTERIMBAUM GRETA·Filed 2009·Granted Jul 24, 2012·12 cites·28 claims
- 0484US10752607B2Polymorphs of N-[(6-cyano-2-fluoro)-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide as kallikrein inhibitorsKALVISTA PHARMACEUTICALS LTD·Filed 2017·Granted Aug 25, 2020·5 cites·37 claims
- 0583US11230537B2Polymorphs of n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[2-oxopyridin-1-yl)methyl]phenyl} methyl)pyrazole-4-carboxamide as iallikrein inhibitorsKALVISTA PHARMACEUTICALS LTD·Filed 2017·Granted Jan 25, 2022·3 cites·11 claims
- 0683US6777399B2Anti-inflammatory androstane derivative compositionsSMITHKLINE BEECHAM CORP·Filed 2002·Granted Aug 17, 2004·16 cites·30 claims
- 0782US8592442B2Nilotinib HCl crystalline formsSTERIMBAUM GRETA·Filed 2012·Granted Nov 26, 2013·9 cites·16 claims
- 0878US12195455B2Succinate and fumarate acid addition salts of piperazine derivativesASCENEURON SA·Filed 2019·Granted Jan 14, 2025·1 cites·2 claims
- 0977US7592329B2Crystalline complexes of fluticasone-2-furoateGLAXO GROUP LTD·Filed 2003·Granted Sep 22, 2009·10 cites·10 claims
- 1076US12398130B2Acid addition salts of piperazine derivativesASCENEURON SA·Filed 2022·Granted Aug 26, 2025·0 cites·6 claims
- 1172US11739068B2Polymorphs of N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide and salts thereofKALVISTA PHARMACEUTICALS LTD·Filed 2021·Granted Aug 29, 2023·0 cites·13 claims
- 1270US2024199573A1Polymorphs of n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide and salts thereofKALVISTA PHARMACEUTICALS LTD·Filed 2023·Application pending·0 cites
- 1362US2023203012A1Solid forms of a plasma kallikrein inhibitor and salts thereofCROWE DAVID MALCOLM·Filed 2023·Application pending·0 cites
- 1454US11584735B2Solid forms of a plasma kallikrein inhibitor and salts thereofKALVISTA PHARMACEUTICALS LTD·Filed 2018·Granted Feb 21, 2023·0 cites·15 claims
- 1553US2004224932A1Novel anti-inflammatory androstane derivative compositionsFiled 2004·Application pending·0 cites
- 1651US2024076301A1Solid Forms of an eIF4E InhibitorPFIZER·Filed 2021·Application pending·0 cites
- 1750US2020325116A1Solid forms of a plasma kallikrein inhibitor and salts thereofKALVISTA PHARMACEUTICALS LTD·Filed 2018·Application pending·0 cites
- 1849US2011245496A1Quinazoline Salt CompoundsCRAIG ANDREW SIMON·Filed 2008·Application pending·0 cites
- 1941US2006094691A1Inclusion complexes of rosiglitazoneCRAIG ANDREW S·Filed 2003·Application pending·0 cites
- 2036US2020317639A1Polymorphs of n-[(2,6-difluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1yl)methyl]phenyl}methyl)pyrazole-4-carboxamideKALVISTA PHARMACEUTICALS LTD·Filed 2017·Application pending·0 cites
- 2134US2006083784A1Amorphous pharmaceutical compositionsSMITHKLINE BEECHAM CORP·Filed 2005·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when David Malcolm Crowe files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →